InMode (INMD) Shareholder Demands Independent Review of CEO-Led Buyout, Cites Conflict of Interest

The Quick Take

• An InMode (INMD) shareholder has formally challenged the CEO-led buyout proposal, citing a fundamental conflict of interest as the CEO serves as both buyer and seller in the management acquisition.
• The shareholder is demanding independent board scrutiny, arguing the proposed consideration may undervalue the aesthetic MedTech company.
• If an independent process runs, competing strategic bidders from the medical device sector could emerge, potentially driving a higher offer.

A major InMode Ltd (INMD) shareholder has publicly challenged the CEO-led acquisition proposal, calling on the company's board to conduct rigorous independent scrutiny of deal terms. The shareholder contends that the CEO's position as lead buyer in a management buyout creates a fundamental conflict of interest — simultaneously representing both the acquiring group and InMode's management. The shareholder demands that independent directors engage separate financial advisors to evaluate whether the proposed consideration reflects fair value, particularly given InMode's operating performance trajectory and sector peer multiples in the aesthetic MedTech space.

InMode specializes in minimally invasive aesthetic medical technology including radiofrequency energy-based devices for body contouring and skin tightening. The company has faced stock price pressure from broader medical aesthetics sector headwinds including competition from newer modalities and reimbursement uncertainty. This depressed price environment can create opportunistic conditions for management-led buyouts where insiders attempt acquisition at compressed valuations before a business or sector cycle recovery. Shareholders challenging such transactions argue the buyout undervalues the company relative to intrinsic value or the multiples comparable devices companies command in change-of-control transactions.

The governance stakes extend beyond INMD. CEO-led buyouts in MedTech have drawn consistent scrutiny from institutional investors and proxy advisory firms ISS and Glass Lewis, which typically recommend shareholder rejection absent a robust independent process and competitive market check. If INMD's board heeds the shareholder's call and runs a formal process, strategic bidders from the medical device sector — larger players seeking tuck-in acquisitions in aesthetic medicine — could emerge with competing bids. Investors should monitor special committee formation, retention of independent financial advisors, and any indication of potential bid price increases through a competitive sale process.

Synthesized from 1 source.